These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 12677174)

  • 1. UGT1A promoter polymorphisms influence bilirubin response to hydroxyurea therapy in sickle cell anemia.
    Heeney MM; Howard TA; Zimmerman SA; Ware RE
    J Lab Clin Med; 2003 Apr; 141(4):279-82. PubMed ID: 12677174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of bilirubin uridine diphosphate-glucuronosyltransferase 1A promoter polymorphisms on serum bilirubin levels and cholelithiasis in children with sickle cell anemia.
    Passon RG; Howard TA; Zimmerman SA; Schultz WH; Ware RE
    J Pediatr Hematol Oncol; 2001 Oct; 23(7):448-51. PubMed ID: 11878580
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic modifiers of sickle cell anemia in the BABY HUG cohort: influence on laboratory and clinical phenotypes.
    Sheehan VA; Luo Z; Flanagan JM; Howard TA; Thompson BW; Wang WC; Kutlar A; Ware RE;
    Am J Hematol; 2013 Jul; 88(7):571-6. PubMed ID: 23606168
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of uridine diphosphate glucuronosyl transferase 1A promoter polymorphisms, beta-globin gene haplotype, co-inherited alpha-thalassemia trait and Hb F on steady-state serum bilirubin levels in sickle cell anemia.
    Adekile A; Kutlar F; McKie K; Addington A; Elam D; Holley L; Clair B; Kutlar A
    Eur J Haematol; 2005 Aug; 75(2):150-5. PubMed ID: 16004608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1 promoter polymorphisms and the development of hyperbilirubinemia and gallbladder disease in children with sickle cell anemia.
    Carpenter SL; Lieff S; Howard TA; Eggleston B; Ware RE
    Am J Hematol; 2008 Oct; 83(10):800-3. PubMed ID: 18756540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of UGT1A1 polymorphism with prevalence and age at onset of cholelithiasis in sickle cell anemia.
    Chaar V; Kéclard L; Diara JP; Leturdu C; Elion J; Krishnamoorthy R; Clayton J; Romana M
    Haematologica; 2005 Feb; 90(2):188-99. PubMed ID: 15710570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of UGT1A1 promoter polymorphism on bilirubin response to hydroxyurea therapy in hemoglobinopathies.
    Italia KY; Jijina FF; Jain D; Merchant R; Nadkarni AH; Mukherjee M; Ghosh K; Colah RB
    Clin Biochem; 2010 Nov; 43(16-17):1329-32. PubMed ID: 20709051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of UGT1A1 promoter polymorphism, α-thalassemia and β
    Batista JVGF; Arcanjo GS; Batista THC; Sobreira MJ; Santana RM; Domingos IF; Hatzlhofer BL; Falcão DA; Pereira-Martins DA; Oliveira JM; Araujo AS; Laranjeira LPM; Medeiros FS; Albuquerque FP; Albuquerque DM; Santos MN; Hazin MF; Dos Anjos AC; Costa FF; Araujo AS; Lucena-Araujo AR; Bezerra MA
    Ann Hematol; 2021 Apr; 100(4):903-911. PubMed ID: 33523291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enalapril and hydroxyurea therapy for children with sickle nephropathy.
    Fitzhugh CD; Wigfall DR; Ware RE
    Pediatr Blood Cancer; 2005 Dec; 45(7):982-5. PubMed ID: 15704213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea for children with sickle cell disease.
    Heeney MM; Ware RE
    Pediatr Clin North Am; 2008 Apr; 55(2):483-501, x. PubMed ID: 18381097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia.
    Silva DG; Belini Junior E; Torres Lde S; Ricci Júnior O; Lobo Cde C; Bonini-Domingos CR; de Almeida EA
    Blood Cells Mol Dis; 2011 Jun; 47(1):23-8. PubMed ID: 21489839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uridine diphosphate glucuronosyl transferase 1A (UGT1A1) promoter polymorphism in young patients with sickle cell anaemia: report of the first cohort study from Nigeria.
    Olatunya OS; Albuquerque DM; Akanbi GO; Aduayi OS; Taiwo AB; Faboya OA; Kayode TS; Leonardo DP; Adekile A; Costa FF
    BMC Med Genet; 2019 Oct; 20(1):160. PubMed ID: 31619193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxyurea therapy associated with declining serum levels of magnesium in children with sickle cell anemia.
    Altura RA; Wang WC; Wynn L; Altura BM; Altura BT
    J Pediatr; 2002 May; 140(5):565-9. PubMed ID: 12032523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
    Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early complication in sickle cell anemia children due to A(TA)nTAA polymorphism at the promoter of UGT1A1 gene.
    Chaouch L; Talbi E; Moumni I; Ben Chaabene A; Kalai M; Chaouachi D; Mallouli F; Ghanem A; Abbes S
    Dis Markers; 2013; 35(2):67-72. PubMed ID: 24167350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy.
    Ware RE; Eggleston B; Redding-Lallinger R; Wang WC; Smith-Whitley K; Daeschner C; Gee B; Styles LA; Helms RW; Kinney TR; Ohene-Frempong K
    Blood; 2002 Jan; 99(1):10-4. PubMed ID: 11756146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
    J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of hydroxyurea in a population of Brazilian patients with sickle cell anemia.
    Vicari P; Barretto de Mello A; Figueiredo MS
    Am J Hematol; 2005 Mar; 78(3):243-4. PubMed ID: 15726590
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.